Industry executives see value in making complete response letters public, but are not expecting to see the US FDA release them anytime soon.
John Maraganore, CEO of Alnylam Pharmaceuticals Inc
Complete Response Letters: Firms See Value In Public Release, Don't Expect It Will Happen
One industry CEO says it would on net be beneficial even though some companies would suffer if they were made public.